23andMe has sold the rights to develop a drug based on its users’ DNA
New Scientist
23andMe has sold the rights to develop a drug based on its users’ DNA
Consumer genomics firm 23andMe has signed its first deal to sell the rights to develop a new drug for inflammatory diseases to a pharmaceutical company